Redx Pharma Plc (LON:REDX – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 15 ($0.20) and traded as high as GBX 33 ($0.44). Redx Pharma shares last traded at GBX 15 ($0.20), with a volume of 1,420,135 shares trading hands.
Redx Pharma Stock Performance
The firm has a market capitalization of £58.35 million, a PE ratio of -150.00 and a beta of -0.53. The company has a quick ratio of 1.93, a current ratio of 1.11 and a debt-to-equity ratio of 527.00. The company has a 50-day moving average of GBX 15 and a 200 day moving average of GBX 15.52.
About Redx Pharma
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
See Also
- Five stocks we like better than Redx Pharma
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Investing In Automotive Stocks
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.